Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lymphoma, Malignant. Basic parameters: from 15 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Efficacy of Management of Patients With Lymphomas Diagnosed at Nimes University Hospital Over 20 Years (1999-2018) Under Real-life Circumstances
Overview
Observation of a cohort of 400 patients with different types of lymphomas.
Detailed description
A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen.
Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results.
The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment.
The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.
Primary outcome measures
- Overall survival rate among patients with Hodgkin Lymphomas [Time frame: 2 years after inclusion]
- Overall survival rate among patients with Mantle-cell Lymphomas [Time frame: 2 years after inclusion]
- Overall survival rate among patients with Primitive Cerebral Lymphomas [Time frame: 2 years after inclusion]
- Overall survival rate among patients with Follicular Lymphomas [Time frame: 2 years after inclusion]
- Overall survival rate among patients with Marginal Zone Lymphomas [Time frame: 2 years after inclusion]
- Overall survival rate among patients with Waldenström's Disease [Time frame: 2 years after inclusion]
Secondary outcome measures (12)
- Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Differences between management of patients with Mantle-cell Lymphomas and data described in the literature. [Time frame: 2 years after inclusion]
- Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature. [Time frame: 2 years after inclusion]
- Differences between management of patients with Follicular Lymphomas and data described in the literature. [Time frame: 2 years after inclusion]
- Differences between management of patients with Marginal Zone Lymphomas and data described in the literature. [Time frame: 2 years after inclusion]
- Differences between management of patients with Waldenström's Disease and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature. [Time frame: 2 years after inclusion]
- Reasons for differences between management of patients with Waldenström's Disease actually observed and data described in the literature. [Time frame: 2 years after inclusion]
Eligibility criteria
Inclusion criteria
- Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.
Exclusion criteria
- Patients aged 18 or over who have expressed their desire not to take part in the study.
- Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.
- Patients under legal guardianship.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU Nimes — Nîmes
Identifiers
NCT: NCT04947618 · NIMAO/2019-01/EJ-01